|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zarogoulidis K, Zarogoulidis P, Darwiche
K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N,
Kougioumtzi I, Karapantzos I, Huang H and Spyratos D: Treatment of
non-small cell lung cancer (NSCLC). J Thorac Dis. 5(Suppl 4):
S389–S396. 2013.PubMed/NCBI
|
|
3
|
Rosell R, Gómez-Codina J, Camps C, Maestre
J, Padille J, Cantó A, Mate JL, Li S, Roig J, Olazábal A, et al: A
randomized trial comparing preoperative chemotherapy plus surgery
with surgery alone in patients with non-small-cell lung cancer. N
Engl J Med. 330:153–158. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Polo V and Besse B: Maintenance strategies
in stage IV non-small-cell lung cancer (NSCLC): In which patients,
with which drugs? Ann Oncol. 25:1283–1293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lwin Z, Riess JW and Gandara D: The
continuing role of chemotherapy for advanced non-small cell lung
cancer in the targeted therapy era. J Thorac Dis. 5(Suppl 5):
S556–S564. 2013.PubMed/NCBI
|
|
6
|
Escuín D and Rosell R: The anti-apoptosis
survivin gene and its role in human cancer: An overview. Clin Lung
Cancer. 1:138–143. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheung CH, Huang CC, Tsai FY, Lee JY,
Cheng SM, Chang YC, Huang YC, Chen SH and Chang JY: Survivin -
biology and potential as a therapeutic target in oncology. Onco
Targets Ther. 6:1453–1462. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang LQ, Wang J, Jiang F, Xu L, Liu FY
and Yin R: Prognostic value of survivin in patients with non-small
cell lung carcinoma: A systematic review with meta-analysis. PloS
One. 7:e341002012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang LN, Wang DS, Chen YQ, Zhao CL, Gong
BL, Jiang AB, Jia W and Hu FD: Expression of survivin and patients
survival in non-small cell lung cancer: A meta-analysis of the
published studies. Mol Biol Rep. 40:917–924. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Scheffer GL, Wijngaard PL, Flens MJ,
Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC and
Scheper RJ: The drug resistance-related protein LRP is the human
major vault protein. Nat Med. 1:578–582. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kickhoefer VA, Rajavel KS, Scheffer GL,
Dalton WS, Scheper RJ and Rome LH: Vaults are up-regulated in
multidrug-resistant cancer cell lines. J Biol Chem. 273:8971–8974.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Izquierdo MA, van der Zee AG, Vermorken
JB, van der Valk P, Beliën JA, Giaccone G, Scheffer GL, Flens MJ,
Pinedo HM, Kenemans P, et al: Drug resistance-associated marker Lrp
for prediction of response to chemotherapy and prognoses in
advanced ovarian carcinoma. J Natl Cancer Inst. 87:1230–1237. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hart SM, Ganeshaguru K, Scheper RJ,
Prentice HG, Hoffbrand AV and Mehta AB: Expression of the human
major vault protein LRP in acute myeloid leukemia. Exp Hematol.
25:1227–1232. 1997.PubMed/NCBI
|
|
15
|
Raaijmakers HG, Izquierdo MA, Lokhorst HM,
de Leeuw C, Belien JA, Bloem AC, Dekker AW, Scheper RJ and
Sonneveld P: Lung-resistance-related protein expression is a
negative predictive factor for response to conventional low but not
to intensified dose alkylating chemotherapy in multiple myeloma.
Blood. 91:1029–1036. 1998.PubMed/NCBI
|
|
16
|
Berger W, Elbling L and Micksche M:
Expression of the major vault protein LRP in human non-small-cell
lung cancer cells: Activation by short-term exposure to
antineoplastic drugs. Int J Cancer. 88:293–300. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Berger W, Setinek U, Hollaus P, Zidek T,
Steiner E, Elbling L, Cantonati H, Attems J, Gsur A and Micksche M:
Multidrug resistance markers P-glycoprotein, multidrug resistance
protein 1, and lung resistance protein in non-small cell lung
cancer: Prognostic implications. J Cancer Res Clin Oncol.
131:355–363. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen ZJ, Le HB, Zhang YK, Qian LY, Sekhar
KR and Li WD: Lung resistance protein and multidrug resistance
protein in non-small cell lung cancer and their clinical
significance. J Int Med Res. 39:1693–1700. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kalemkerian GP, Akerley W, Bogner P,
Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R,
Grecula JC, et al: National Comprehensive Cancer Network: Small
cell lung cancer. J Natl Compr Canc Netw. 11:78–98. 2013.PubMed/NCBI
|
|
20
|
Brambilla E, Travis WD, Colby TV, Corrin B
and Shimosato Y: The new World Health Organization classification
of lung tumours. Eur Respir J. 18:1059–1068. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dingemans AM, van Ark-Otte J, van der Valk
P, Apolinario RM, Scheper RJ, Postmus PE and Giaccone G: Expression
of the human major vault protein LRP in human lung cancer samples
and normal lung tissues. Ann Oncol. 7:625–630. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Klunder JW, Komdeur R, van der Graaf WT,
et al: Expression of multidrug resistance-associated proteins in
rhabdomyosarcomas before and after chemotherapy: The relationship
between lung resistance-related protein (LRP) and differentiation.
Hum Pathol. 34:150–155. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Karczmarek-Borowska B, Filip A,
Wojcierowski J, Smoleń A, Pilecka I and Jabłonka A: Survivin
antiapoptotic gene expression as a prognostic factor in non-small
cell lung cancer: In situ hybridization study. Folia
Histochem Cytobiol. 43:237–242. 2005.PubMed/NCBI
|
|
25
|
Scheper RJ, Broxterman HJ, Scheffer GL,
Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML,
de Vries EG, van der Valk P, et al: Overexpression of a M(r)
110,000 vesicular protein in non-P-glycoprotein-mediated multidrug
resistance. Cancer Res. 53:1475–1479. 1993.PubMed/NCBI
|
|
26
|
Young LC, Campling BG, Cole SP, Deeley RG
and Gerlach JH: Multidrug resistance proteins MRP3, MRP1, and MRP2
in lung cancer: Correlation of protein levels with drug response
and messenger RNA levels. Clin Cancer Res. 7:1798–1804.
2001.PubMed/NCBI
|
|
27
|
Young LC, Campling BG, Voskoglou-Nomikos
T, Cole SP, Deeley RG and Gerlach JH: Expression of multidrug
resistance protein-related genes in lung cancer: Correlation with
drug response. Clin Cancer Res. 5:673–680. 1999.PubMed/NCBI
|
|
28
|
Harada T, Ogura S, Yamazaki K, Kinoshita
I, Itoh T, Isobe H, Yamashiro K, Dosaka-Akita H and Nishimura M:
Predictive value of expression of P53, Bcl-2 and lung
resistance-related protein for response to chemotherapy in
non-small cell lung cancers. Cancer Sci. 94:394–399. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dingemans AC, van Ark-Otte J, Span S,
Scagliotti GV, van der Valk P, Postmus PE and Giaccone G:
Topoisomerase IIalpha and other drug resistance markers in advanced
non-small cell lung cancer. Lung Cancer. 32:117–128. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang TB, Zhang NL, Wang SH, Li HY, Chen SW
and Zheng YG: Expression of ERCC1 and BRCA1 predict the clinical
outcome of non-small cell lung cancer in patients receiving
platinum-based chemotherapy. Genet Mol Res. 13:3704–3710. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xie KJ, He HE, Sun AJ, Liu XB, Sun LP and
Dong XJ: Expression of ERCC1, MSH2 and PARP1 in non-small cell lung
cancer and prognostic value in patients treated with platinum-based
chemotherapy. Asian Pac J Cancer Prev. 15:2591–2596. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kaira K, Yamamoto N, Kenmotsu H, Murakami
H, Ono A, Naito T, Endo M and Takahashi T: Prognostic impact of
18F-FDG uptake on PET in non-small cell lung cancer patients with
postoperative recurrence following platinum-based chemotherapy.
Respir Investig. 52:121–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yamashita S, Chujo M, Miyawaki M, Tokuishi
K, Anami K, Yamamoto S and Kawahara K: Combination of p53AIP1 and
survivin expression is a powerful prognostic marker in non-small
cell lung cancer. J Exp Clin Cancer Res. 28:222009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Naumnik W, Nilklińska W, Ossolińska M and
Chyczewska E: Serum levels of HMGB1, survivin, and VEGF in patients
with advanced non-small cell lung cancer during chemotherapy. Folia
Histochem Cytobiol. 47:703–709. 2009.PubMed/NCBI
|
|
35
|
Hu S, Qu Y, Xu X, Xu Q, Geng J and Xu J:
Nuclear survivin and its relationship to DNA damage repair genes in
non-small cell lung cancer investigated using tissue array. PloS
One. 8:e741612013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Stewart DJ: Tumor and host factors that
may limit efficacy of chemotherapy in non-small cell and small cell
lung cancer. Crit Rev Oncol Hematol. 75:173–234. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Singhal S, Vachani A, Antin-Ozerkis D,
Kaiser LR and Albelda SM: Prognostic implications of cell cycle,
apoptosis, and angiogenesis biomarkers in non-small cell lung
cancer: A review. Clin Cancer Res. 11:3974–3986. 2005. View Article : Google Scholar : PubMed/NCBI
|
